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ABSTRACT
Hematopoiesis is the process of blood cell formation starting from hematopoietic stem/progenitor
cells (HSPCs). The understanding of regulatory networks involved in hematopoiesis and their
impact on gene expression is crucial to decipher the molecular mechanisms that control hemato-
poietic development in physiological and pathological conditions, and to develop novel therapeutic
strategies. An increasing number of epigenetic studies aim at defining, on a genome-wide scale,
the cis-regulatory sequences (e.g., promoters and enhancers) used by human HSPCs and their
lineage-restricted progeny at different stages of development. In parallel, human genetic studies
allowed the discovery of genetic variants mapping to cis-regulatory elements and associated with
hematological phenotypes and diseases. Here, we summarize recent epigenetic and genetic studies
in hematopoietic cells that give insights into human hematopoiesis and provide a knowledge basis
for the development of novel therapeutic approaches. As an example, we discuss the therapeutic
approaches targeting cis-regulatory regions to reactivate fetal hemoglobin for the treatment of b-
hemoglobinopathies. Epigenetic studies allowed the definition of cis-regulatory sequences used by
human hematopoietic cells. Promoters and enhancers are targeted by transcription factors and are
characterized by specific histone modifications. Genetic variants mapping to cis-regulatory ele-
ments are often associated with hematological phenotypes and diseases. In some cases, these var-
iants can alter the binding of transcription factors, thus changing the expression of the target
genes. Targeting cis-regulatory sequences represents a promising therapeutic approach for many
hematological diseases. STEM CELLS TRANSLATIONAL MEDICINE 2017;00:000–000
SIGNIFICANCE STATEMENT
This review summarizes the epigenetic and genetic studies identifying genes and cis-regulatory
regions involved in normal and pathological hematopoiesis. We discuss novel potential thera-
peutic approaches targeting cis-regulatory sequences, which hold great promise for the treat-
ment many hematological diseases. The readers will gain an overview of the epigenetic
mechanisms regulating hematopoiesis and acquire knowledge about genome editing-based
approaches for the treatment of b-hemoglobinopathies.
INTRODUCTION
Different cell types from the same organism or tis-
sue are genetically identical but functionally het-
erogeneous because of the differential expression
of genes. Epigenetic modifications are responsible
for changes in gene activity that are not strictly
dependent on the DNA sequence. Epigenetic
markers can be used to identify cis-regulatory
DNA elements (e.g., promoters and enhancers)
that mediate developmental stage- and tissue-
specific gene expression. High-throughput
sequencing technologies have been extensively
used to study the epigenetic regulation of gene
expression programs in a wide range of hemato-
poietic cell types. The definition of regulatory
regions controlling cell-specific gene expression
programs is fundamental to understand the
molecular mechanisms underlying hematopoiesis
in health and disease.
HUMAN HEMATOPOIESIS
Human blood contains several different cell types
with specific functions. Erythrocytes, also known
as red blood cells (RBCs), transport oxygen from
the lungs to the tissues and remove carbon diox-
ide. Leukocytes, also known as white blood cells
(WBCs), are involved in inflammatory reaction
and immune response. WBCs comprise granulo-
cytes (neutrophils, basophils, eosinophils, and
mast cells), lymphocytes (T cells, B cells, and natu-
ral killer [NK] cells), monocytes/macrophages, and
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ENABLING TECHNOLOGIES FOR CELL-BASED CLINICAL
TRANSLATION
dendritic cells. Platelets are cell fragments derived from megakar-
yocytes and play an essential role in the maintenance of hemosta-
sis (Fig. 1).
Hematopoietic stem cells (HSCs) sustain the life-long produc-
tion of all blood cells thanks to their ability to self-renew and dif-
ferentiate toward multiple lineages. The hierarchical model of
hematopoiesis places HSCs at the root of the tree composed of a
series of multipotent, oligopotent, and unipotent progenitors that
finally differentiate toward mature hematopoietic cells. Multipo-
tent progenitor cells (MPPs), the immediate progeny of HSCs,
have a full lineage potential but a limited self-renewal ability.
MPPs give rise to oligopotent progenitors: the common myeloid
progenitors (CMPs) and the multilymphoid progenitors (MLPs) [1].
CMPs differentiate into the granulocyte/macrophage progenitors
(GMPs) and the megakaryocyte/erythroid progenitors (MEPs),
which then give rise to unilineage progenitors and mature precur-
sors. MLPs are able to generate both GMPs and the common
lymphoid progenitors, which differentiate into B, T, and NK cell
precursors (Fig. 1).
This current model of hematopoiesis (reviewed in [2]) is based
on prospective isolation of hematopoietic cells carrying specific
surface markers and evaluation of the lineage output using in vitro
or in vivo assays. However, several studies at single-cell level chal-
lenged the classical hierarchy of human hematopoiesis. Combining
new sorting strategies, optimized single-cell functional assays and
single-cell gene expression profiling, Notta et al. showed that, in
adult bone marrow, classically defined CMPs and MEPs are
heterogeneous populations, composed mostly of unilineage com-
mitted cells [3]. Therefore, multipotent cells, such as HSCs and
MPPs, give rise to committed unipotent progenitors, without an
intermediate oligopotent CMP and MEP stage. Furthermore, the
study of Velten et al. showed that HSCs and their immediate prog-
eny, such as MPPs and MLPs, do not represent discrete cell types,
but are included in a continuum of low-primed undifferentiated
(CLOUD)-hematopoietic stem/progenitor cells (HSPCs) [4]. In the
CLOUD, HSCs gradually acquire continuous transcriptomic lineage
priming into lympho/myeloid or megakaryocytic/erythroid major
branches.
Despite these recent single-cell studies suggesting a revision
of the hierarchical organization of human hematopoiesis, the cur-
rent model is suitable and widely used to investigate the molecu-
lar mechanisms that drive HSPCs commitment and differentiation.
EPIGENETIC CONTROL OF GENE EXPRESSION
Gene expression is regulated by transcription factors and cofactors
binding cis-regulatory DNA sequences, such as promoters and
enhancers. Promoters are located at the 50 end of the genes and
consist of multiple DNA motifs for transcription factors that recruit
the transcriptional machinery and define the transcription start
site (TSS) [5]. Enhancers are clusters of transcription factors bind-
ing sites and can increase the transcription of the target pro-
moters [5–7]. Enhancers function at various distances from their
target genes and can be located upstream or downstream of
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Figure 1. The current model of human hematopoiesis. Schematic representation of the hematopoietic hierarchical tree, composed of multi-
potent, oligopotent, and unipotent cell types. Abbreviations: B, B cells; Baso, basophils; CLP, common lymphoid progenitor; CMP, common
myeloid progenitor; DC, dendritic cells; Eos, eosinophils; Ery, erythrocytes; GMP, granulocyte/macrophage progenitor; HSC, hematopoietic
stem cell; MC, mast cells; MEP, megakaryocyte/erythroid progenitor; Mk/Pla, megakaryocytes/platelets; MLP, multilymphoid progenitor; M/
M, monocytes/macrophages; MPP, multipotent progenitor cell; Neutr, neutrophils; NK, natural killer cells; T, T cells.
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genes or within introns. Chromatin looping is thought to bring
promoters and enhancers in close proximity to activate gene tran-
scription. Enhancers are fundamental for the spatial- and
temporal-specific expression of genes. These regulatory elements
can be cell type-specific: distinct enhancer elements can act on
the same gene at different cellular stages or in different tissues, as
well as in response to different stimuli. More recently, super-
enhancers have been defined as clusters of cell-specific enhancers
densely occupied by transcription factors and cofactors, and
involved in the regulation of genes specifying cell identity [8].
Cis-regulatory elements present characteristic epigenetic fea-
tures. They are typically devoid of nucleosomes to allow the bind-
ing of transcription factors to their DNA motifs [9, 10].
Nucleosomes surrounding these highly accessible DNA sequences
are characterized by specific histone modifications. Histone H3
lysine 4 trimethylation (H3K4me3) and monomethylation
(H3K4me1) are preferentially associated with promoters and
enhancers, respectively [9, 11]. Lysine 27 acetylation of histone H3
(H3K27ac) marks highly active promoters and enhancers, and
super-enhancers [8, 11, 12] (Fig. 2). Histone modifying enzymes
that act as transcriptional coactivators, such as the histone acetyl-
transferase p300 and CREB binding protein (CBP), are localized in
active regulatory elements, in particular enhancers [9, 13].
In the last 10 years, epigenetic features characteristic of tran-
scriptional regulatory regions (DNA accessibility, histone marks,
transcription factors, and cofactors binding) have allowed the
mapping of cis-regulatory elements genome-wide in a multitude
of human cell lines, primary cells, and tissues, thanks to different
high-throughput technologies based on next-generation sequenc-
ing (NGS) [7, 9]. Chromatin accessibility can be directly assessed
with different approaches: DNase-seq, formaldehyde-assisted iso-
lation of regulatory elements (FAIRE)-seq, and assay for
transposase-accessible chromatin using sequencing (ATAC-seq)
[9]. DNase-seq detects accessible DNA by DNaseI enzymatic diges-
tion of nucleosome-depleted sites, also known as DNaseI hyper-
sensitive (HS) sites, which represent cis-regulatory elements [14].
FAIRE-seq (formaldehyde assisted isolation of regulatory elements
coupled with NGS) determines open chromatin regions by
sequencing protein-free DNA, after removal of formaldehyde
crosslinked protein-DNA complexes [15]. ATAC-seq is based on the
ability of the hyperactive Tn5 transposase to fragment DNA and
integrate sequencing adapters into open chromatin regions [16].
Chromatin immunoprecipitation (ChIP) combined with NGS (ChIP-
seq) [17, 18] is also widely used to study chromatin modifications
typical of cis-regulatory elements. ChIP-seq profile of H3K4me3
allows the identification of promoter regions [9, 17, 18], while
H3K4me1 analysis defines enhancer regions [9]. H3K27ac can be
used alone or integrated with H3K4 methylation profiles to iden-
tify highly active promoters and enhancers, and super-enhancers
[8, 19, 20]. ChIP-seq analysis of binding sites of multiple transcrip-
tion factors and/or coactivator proteins, such as p300 and CBP
acetyltransferase, can also be used to identify enhancer regions
[9, 21, 22].
Human hematopoiesis is one of the most established cell dif-
ferentiation systems and is amenable to the study of gene tran-
scription and chromatin structure. The transition through the
hematopoietic hierarchy is regulated at transcriptional level. Mas-
ter transcription factors control the activation of lineage-specific
transcriptional programs through the binding of cis-regulatory ele-
ments. The identification of enhancers is a key step to understand
how gene expression is finely regulated during hematopoiesis and
how it is altered in pathological conditions [23]. Enhancers estab-
lish not only the transcription level, but also when and where a
gene is expressed, thus determining cell identity. Most of the epi-
genetic studies characterizing the regulatory landscape of human
hematopoietic cells rely on the prospective isolation of the differ-
ent cell types defined using specific panels of surface markers
(Fig. 1). In the last years, large international consortia, such as
ENCODE (http://www.encodeproject.org), Roadmap Epigenomics
(http://www.roadmapepigenomics.org), and Blueprint Epigenome
(http://www.blueprint-epigenome.eu) collected epigenetic data
of several human hematopoietic cell types, including rare blood
cells [24–26]. These data represent an important public resource
for basic biology and disease-oriented research. Several studies
investigated the regulatory landscape of HSPCs in comparison
with lineage-restricted progenitors or mature cells and described
changes in enhancer dynamics during erythroid [27–31], myeloid
[30–32], and lymphoid [28, 31, 32] commitment and differentia-
tion. These studies showed that each individual cell type, within
the hematopoietic hierarchy, displayed a set of cell-specific cis-reg-
ulatory regions associated to genes involved in cellular functions
related to the given cell type. Interestingly, enhancer and super-
enhancer landscape better define cell identity, compared with
transcriptomic profile and promoter usage [12, 30, 31].
INSIGHTS INTO HUMAN HEMATOPOIESIS FROM GENETIC AND
EPIGENETIC STUDIES
Human genetic studies allow the identification of DNA variants
mapping to epigenetically defined regulatory regions and influenc-
ing gene expression. Genome-wide association studies (GWASs)
allow the identification of sequence variations (single nucleotide
polymorphisms [SNPs]) associated with human phenotypes and
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Figure 2. Genetic variants in cis-regulatory elements affect target
gene expression. Genetic variants mapping to enhancers or pro-
moters (indicated by yellow and blue stars, respectively) can pre-
vent the binding of transcription factors and result in decreased
expression of the target genes (e.g., CCND3, CEBPA, ALAS2, UROS,
PKLR, and HBD). Active enhancers are characterized by H3K4me1
and H3K27ac histone marks, whereas H3K27ac and H3K4me3 mark
active promoters. Abbreviations: prom, promoter; enh, enhancer;
TF, transcription factor.
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diseases, which are collected in large databases, such as the
GWAS Catalog [33] and GWASdb [34]. An increasing number of
GWASs identified genetic variants linked to a variety of traits,
ranging from height and hair color to metabolic and hematological
phenotypes. SNPs can be also associated to disease susceptibility
and represent genetic modifiers of diseases. Interestingly, numer-
ous trait- and disease-associated sequence variations occur in cis-
regulatory elements, such as enhancers [24–26, 35, 36]. Genes
potentially targeted by regulatory elements associated with these
SNPs are then identified as: (a) the nearest genes, (b) genes
whose expression is correlated with the specific sequence varia-
tion (expression quantitative trait loci SNPs), (c) genes potentially
implicated in the phenotype.
Several GWASs identified SNPs associated with hematological
phenotypes [37–40]. Large studies described 68 genetic loci linked
with platelet number and size [38], and 10 SNPs associated with
WBCs number and subtypes [40]. Seventy-five genetic loci have
been associated with RBC traits, such as RBC number and size
(mean corpuscular volume [MCV]), hematocrit, and hemoglobin
concentration [37]. In this study, a large fraction of SNPs co-
mapped with epigenetically defined erythroid enhancers [37].
SNPs associated with cis-regulatory elements have in general
small effects on gene transcription and disease phenotypes,
explaining less than 10% of phenotypic variance, but can give us
insights into human hematopoiesis in vivo. Indeed, they allow the
discovery of new candidate genes involved in hematopoiesis [37,
38, 40, 41] and hematopoietic disorders [42, 43]. Interestingly,
mutations in regulatory elements have been shown to be respon-
sible for several genetic and nongenetic hematological diseases
[44–51].
Genetic variants mapping to cis-regulatory elements can be
experimentally validated to unravel the molecular mechanisms
underlying the observed phenotypes. They can affect enhancer
and promoter activity, for example, by either disrupting or creat-
ing de novo binding sites for transcription factors, thus deregulat-
ing the expression of the target genes [46, 52–54] (Figs. 2, 3).
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Figure 3. Genetic variants in the b-globin locus, HBS1L-MYB, and BCL11A loci influence fetal hemoglobin (HbF) levels. (A): Schematic repre-
sentation of the b-globin locus on chromosome 11. Point mutations (HPFH 2175 T>C and HPFH 2198 T> C upstream of the g-globin tran-
scription start sites [TSSs]) and deletions (HPFH 13-bp in Ag-globin promoter and HPFH-5) are associated with HPFH. The 2175 T> C and
2198 T>C mutations create binding sites for TAL1 and KLF1 transcriptional activators. A common SNP at position 2158 bp of the Gg-globin
promoter is associated with moderately high levels of HbF. LCR and b-like globin genes (embryonic E, fetal Ag and Gg, and adult d and b) are
indicated. (B): The region between HBS1L and MYB genes on chromosome 6 contains three HMIP blocks 1, 2, and 3. Five SNPs associated
with higher HbF levels map to the 284 and 271 kb MYB enhancers in HMIP-2. These variants reduce LDB1, GATA1, and KLF1 occupancy,
thus decreasing MYB expression and, as a consequence, increasing HbF expression. (C): Representation of the BCL11A gene on chromosome
2. Several SNPs, associated with high HbF levels map to three erythroid-specific intronic enhancers located 55, 58, and 62 kb downstream of
the BCL11A TSS. A SNP within the 162 kb enhancer impairs GATA1 and TAL1 binding, thus leading to a reduction of BCL11A expression and
increase of HbF levels. Targeted disruption of a GATA1 binding site in the 158 kb enhancer is also associated with decreased BCL11A levels
and high HbF expression. Abbreviations: HMIP, HBS1L-MYB intergenic polymorphism; HPFH, hereditary persistence of fetal hemoglobin; LCR,
locus control region; SNP, single nucleotide polymorphism.
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Functional and mechanistic studies can be focused on the genes
associated with the cis-regulatory regions and potentially involved
in hematopoiesis. As an example, GWASs identified a SNP associ-
ated with low RBC number and high MCV in an enhancer region
located 15 kb upstream of the cyclin D3 gene (CCND3) (Fig. 2) [39,
55]. Starting from this observation, Sankaran et al. unraveled the
role of cyclin D3 in the regulation of erythrocyte number and size
through gene disruption studies [41]. Other studies dissected the
regulatory elements harboring genetic variants associated with
particular phenotypes [46, 56]. A recent GWAS identified a SNP,
associated with low basophil counts, 39 kb downstream of the
gene encoding CCAAT/enhancer binding protein alpha (CEBPA), a
master regulator implicated in basophil specification [56, 57]. This
SNP overlaps with an enhancer targeted by the myeloid master
regulators GATA2 and RUNX1 and identified specifically in CMPs,
which give rise to several lineages including basophils. CRISPR-
Cas9-mediated mutagenesis of this region in HSPCs led to CEBPA
downregulation and impairment of basophil production and mat-
uration (Fig. 2) [56]. Interestingly, disease-causing variants affect-
ing the binding sites of the erythroid master regulator GATA1
were identified in regulatory elements of the ALAS2 [44, 45],
UROS [47], PKLR [48], and HBD [49] genes. Loss of GATA1 binding
at promoter or enhancer regions was associated with decreased
expression of the target gene (Fig. 2), which can lead to severe
clinical phenotypes (e.g., X-linked sideroblastic anemia for ALAS2,
congenital erythropoietic porphyria for UROS and pyruvate kinase
deficiency for PKLR). Initial validation studies based on electropho-
retic mobility shift and luciferase assays showed that these muta-
tions impair GATA1 binding and the enhancer or promoter activity
[45, 47, 49]. More recently, CRISPR-Cas9-mediated in situ disrup-
tion of the GATA1 motifs present in the ALAS2, UROS, and PKLR
regulatory regions reproduced the gene downregulation observed
in patients harboring mutation of these binding sites [46]. Inter-
estingly, the disruption of the GATA1 motifs seems to affect the
binding of the GATA1-dependent activation complex [46].
CIS-REGULATORY REGIONS AS GENETIC MODIFIERS OF FETAL
HEMOGLOBIN
Hemoglobin (Hb) is a tetrameric protein containing two a-like and
two b-like globins. The b-like globin genes (embryonic E, fetal Ag
and Gg, adult d and b) are located on chromosome 11 within the
b-globin gene cluster. Here, these genes are under the control of
the b-globin locus control region (LCR), composed of DNase I HSs.
The LCR is able to recruit transcription factors and interact with
the different b-like globin gene promoters to regulate their
expression during development. A g-to-b globin switching occurs
shortly after birth. In adulthood, the expression of fetal hemoglo-
bin (HbF, a2g2) is reduced to <1% of the total Hb output and the
major Hb type is HbA (a2b2). b-hemoglobinopathies are the
most common genetic disorders worldwide and are characterized
by reduced or abnormal production of adult b-chains. In b-
thalassemia, mutations affecting b-globin chain production cause
the precipitation of unpaired a-globin chains within erythroid pre-
cursors, leading to their death and thereby causing ineffective pro-
duction of RBCs. In sickle cell disease (SCD), a single amino acid
substitution (E6V) in the b-globin chain causes the production of
sickle hemoglobin (HbS). HbS has the propensity to polymerize
and precipitate under deoxygenated conditions, resulting in RBC
deformation and vaso-occlusions.
b-thalassemia and SCD display a remarkable variability in the
clinical severity. However, reasons explaining this heterogeneity
are not fully understood. Different studies have shown that inter-
individual variation in HbF expression may influence the clinical
outcome of these pathologies, with high HbF levels correlated
with less severe complications and longer life expectancy [58–60].
In b-thalassemia, g-globin compensates the b-globin deficiency,
whereas in SCD it exerts a potent anti-sickling effect thanks to a
critical amino acid blocking the lateral contacts between b-like
globin chains required for the formation of HbS polymers.
A benign syndrome, referred to as “hereditary persistence of
fetal hemoglobin” (HPFH), is characterized by increased HbF levels
(up to 90% of the total Hb) in the adult life without major impair-
ment of RBC indices [61]. Molecular studies have identified two
different types of HPFH, either caused by large deletions encom-
passing the b- and d-genes (13–106 kb; e.g., HPFH5) or due to
point mutations in the g-globin promoters (Fig. 3A). Deletional
HPFH are thought to either juxtapose the g-globin promoters to
enhancers normally located far away from the g-globin genes or
remove g-globin inhibitory sequences [61, 62]. Non-deletional
HPFH may alter the binding of transcription factors to critical
regions of the g-globin promoters. These mutations occur in three
distinct regions of the highly similar g-globin promoters: (a)
approximately 200 bp upstream of the TSS of the g-globin genes.
The 2198 bp T> C mutation in the Ag-globin promoter has been
recently shown to generate a de novo binding site for the ery-
throid transcriptional activator KLF1 [63], (b) at position 2175 bp
where the mutation T> C in both the g-promoters creates a bind-
ing site for TAL1, a transcription factor activating the expression of
many erythroid-specific genes [52], (c) between 2117 and 2102
bp within the CCAAT box and direct repeat (DR) elements targeted
by potential HbF repressors, such as NR2F2 (COUP-TFII), NR2C1
(TR2), and NR2C2 (TR4) [64]. A 13-bp HPFH deletion (2114 to
2102 bp) disrupting the CCAAT box and the DR elements of the
Ag-globin gene has also been described [61, 65] (Fig. 3A).
HPFH large deletions and point mutations are frequently asso-
ciated with a pancellular HbF distribution among the erythrocytes.
Interestingly, pancellular HbF expression in compound heterozy-
gous with SCD and HPFH traits results in absent or milder SCD
symptoms [61]. As an example, SCD-HPFH individuals have no fea-
tures of SCD, including vaso-occlusive events and hemolytic ane-
mia [66]. Beside HPFH mutations, other genetic factors can
moderately raise HbF levels above 1% of the total Hb and are
associated with heterocellular HbF distribution. Patients showing
heterocellular HbF expression still display anemia and vaso-
occlusive complications, albeit less severe than in SCD [67]. Nota-
bly, this condition was associated with reduced pain crisis rate in
SCD patients [68]. Genetic studies identified sequence variations
at three genomic loci (b-globin locus, HBS1L-MYB, and BCL11A)
that account for>30% of the variance in HbF levels [69–71].
In the b-globin locus, a common SNP (C> T; commonly
referred to as the “XmnI site”) at position2158 bp of the Gg-glo-
bin promoter (chromosome 11p15) was linked with moderately
high HbF levels [71–73] (Fig. 3A). Other SNPs associated with HbF
levels were mapped in the b-globin locus [74, 75]. However, the
functional cis-regulatory elements targeted by these SNPs have
not been identified yet. Polymorphisms of the b-globin locus
alone cannot explain the considerable variance in HbF levels, as
demonstrated by studies showing that high HbF determinant seg-
regates independently of the b-globin gene cluster [68, 76, 77],
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thus suggesting the involvement of other QTLs in the modulation
of g-globin expression.
Craig and colleagues demonstrated in a large kindred that
another major determinant of HbF production is located on chro-
mosome 6q23-q24 [78]. Further studies identified multiple
genetic variants on chromosome 6q23 that are strongly associ-
ated with HbF levels [70]. These SNPs are distributed in three
genomic regions (referred to as HBS1L-MYB intergenic polymor-
phism [HMIP] blocks 1, 2, and 3) that span a 79-kb segment from
the guanosine triphosphate (GTP)-binding elongation factor
HBS1L gene to 45 kb upstream of the myeloblastosis oncogene
MYB gene (Fig. 3B). HMIP block 2 contains SNPs that are strongly
associated with HbF and erythroid traits. Among these variants,
five SNPs were mapped in two epigenetically defined erythroid-
specific enhancers, located 84 and 71 kb upstream of the MYB
TSS [79]. These variants impaired the binding of the looping factor
LDB1 and GATA1, TAL1 and KLF1 erythroid master regulators (Fig.
3B). As a consequence, the long-range interaction between the
erythroid-specific enhancers and MYB promoter were decreased,
as well as MYB expression [79]. CRISPR-Cas9 mutagenesis con-
firmed the genetic association of the 284 and 271 kb enhancer
regions with MYB expression levels [80]. MYB downregulation
was associated with moderately increased HbF levels [79]. Lower
MYB levels lead to a slow cell-cycle progression, which is associ-
ated with increased F-cell production. Alternatively, increased
HbF levels can be ascribed to the failed activation of genes encod-
ing HbF repressors (e.g., BCL11A) by MYB [79] (Fig. 3B).
A GWAS performed in individuals with contrasting extreme
F-cell distribution (below the 5th or above the 95th percentile)
mapped an additional QTL in the gene encoding the zinc-finger
transcription factor BCL11A on chromosome 2p15 [69]. Other
GWASs validated the association between several SNPs in the
BCL11A locus and higher HbF levels [68, 81–83]. These SNPs lie in
an erythroid-specific intronic super-enhancer composed of three
constituent enhancers located 55, 58, and 62 kb downstream of
the BCL11A TSS (155,158, and162 DNase HS) [84, 85] (Fig. 3C).
A sequence variant in the 162 DNase HS affects the binding of
GATA1 and TAL1 transcription factors, leading to a modest reduc-
tion of BCL11A expression and increased HbF levels in a SCD
cohort [84] (Fig. 3C). These observations suggested a role of
BCL11A in the repression of HbF expression in adult life. Further
studies showed that shRNA-knockdown of BCL11A in primary ery-
throid cells increased g-globin expression [86]. Notably, inactiva-
tion of BCL11A led to the correction of the murine SCD
phenotype by inducing pancellular HbF expression [87].
THERAPEUTIC STRATEGIES FOR b-HEMOGLOBINOPATHIES
TARGETING CIS-REGULATORY REGIONS
Current treatments for SCD and b-thalassemia involve sympto-
matic care and RBC transfusions, which, however, can lead to iron
overload and organ damage. The only definitive cure for b-
hemoglobinopathies is the allogeneic HSC transplantation, which
is available to a small proportion (30%) of the patients with an
human leukocyte antigen (HLA)-compatible donor [88]. Transplan-
tation of autologous genetically corrected HSCs is considered an
attractive therapeutic alternative for patients lacking a suitable
donor. Gene therapy trials based on the use of lentiviral vectors
expressing a b-globin transgene are currently ongoing [89–93].
Alternative promising approaches aim at reactivating therapeutic
HbF expression [54]. Many of these strategies are based on tar-
geted genome editing of cis-regulatory elements [85, 94–96].
Several groups attempted to mimic the beneficial HPFH muta-
tions in the Ag- and/or Gg-globin gene promoters. HPFH mutations
in the g-globin promoters may disrupt binding sites for g-globin
silencers [94] or generate new binding sites for g-globin activators
[52, 63] (Fig. 3A). Traxler et al. reproduced the 13-bp HPFH deletion
in the g-globin promoters using the CRISPR/Cas9 system, thereby
inducing HbF levels sufficient to inhibit HbS polymerization in SCD
HSPC-derived erythrocytes. This deletion is thought to reactivate
fetal genes by removing the CCAAT box and the DR element, thus
disrupting the binding sites for g-globin transcriptional repressors
[97]. The introduction of HPFH point mutations represents a poten-
tial strategy to reactivate HbF expression. In erythroid cell lines, the
insertion of 2175T> C or the 2198T> C substitutions in the g-
globin promoters created de novo binding sites for transcriptional
activators, and induced loop formation between the LCR and g-
globin promoters, thus increasing HbF expression (Fig. 3A) [52, 63].
This potential therapeutic approach has not yet been explored in
human HSPCs. Another strategy aims at recreating deletional
HPFH, removing the b- and d-globin genes and the putative g-
globin inhibitory sequences. Ye et al. explored a CRISPR/Cas9 strat-
egy in normal donor-derived HSPCs to excise a 12.9-kb region
deleted in HPFH individuals (HPFH-5; Fig. 3A) [95, 98]. This
approach resulted in a significant g-globin induction and downreg-
ulation of the b-globin expression in HSPC-derived erythrocytes.
Downregulation of factors responsible for fetal g-globin
repression can be explored to achieve therapeutic HbF expression.
Over the past decades, molecular studies unraveled the role of
several nuclear factors in the regulation of the fetal-to-adult
hemoglobin switching [99, 100]. However, interfering with the
expression of HbF repressors, such as MYB, leukemia/lymphoma-
related factor (LRF), KLF1, and BCL11A, can impair terminal eryth-
ropoiesis and the development of multiple hematopoietic line-
ages. MYB is essential for the hematopoietic system development
[101] and its downregulation in human HSPCs determines a cell-
cycle arrest and impairs erythroid differentiation [102]. The tran-
scription factor LRF, encoded by the ZBTB7A gene, is necessary for
HSC maintenance and B cell commitment [103]. In mice, loss of
LRF leads to lethal anemia, due to increased apoptosis of ery-
throid precursors [104], and LRF knockdown increases HbF expres-
sion but delays human erythroid differentiation [105, 106]. KLF1 is
a transcriptional regulator promoting erythroid lineage develop-
ment at the expense of the megakaryocytic compartment [107,
108] and KLF1 knockout mice die in utero from severe anemia
[109]. Although KLF1 haploinsufficiency can induce HbF expres-
sion [110], KLF1 is not an ideal target to develop a safe therapy for
b-hemoglobinopathies, given its essential role in erythropoiesis.
BCL11A is essential for proper development of B cells and
BCL11A-deficient HSCs showed cell cycle and multi-lineage differ-
entiation defects [111]. Therefore, erythroid-restricted BCL11A
knockdown is mandatory. Interestingly, erythroid-specific expres-
sion of a shRNA targeting BCL11A induced HbF reactivation in nor-
mal donor and SCD erythrocytes circumventing HSC toxicity [112].
Recently, Chang et al. showed that complete BCL11A knockdown
impair RBC enucleation [113]. However, in humans, BCL11A hap-
loinsufficiency is associated with HbF persistence with normal
hematological functions [114], suggesting that a fine modulation
of BCL11A expression is required to develop a safe therapeutic
strategy for b-hemoglobinopathies. An alternative strategy is
based on the disruption of erythroid-specific BCL11A enhancers,
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allowing a fine tuning of BCL11A expression. CRISPR/Cas9 dissec-
tion of BCL11A intronic enhancers identified a potential GATA1
binding site in the 158 DNase HS critical for erythroid expression
of BCL11A (Fig. 3C) [85]. CRISPR/Cas9 and zinc finger nuclease-
mediated disruption of this GATA1 motif led to reasonably
decreased BCL11A expression and increased HbF levels in human
erythrocytes [85, 96]. Importantly, targeting of the BCL11A
erythroid-specific enhancer did not affect RBC enucleation [113].
For a potential clinical application of these novel approaches
aimed at reactivating HbF expression, further studies are required
to: (a) assess the frequency of genome edited bona fide human
HSCs. To this aim, the delivery and the activity of the genome edit-
ing tools have to be optimized; (b) evaluate the potential toxicity
due to the delivery and the on- and off-target activity of the
genome editing tools in HSCs and their progeny; (c) perform a
proper comparison of the different therapeutic strategies in terms
of Hb content and functional correction of the patient phenotype.
CONCLUSION
In summary, the combination of genetic and epigenetic studies
enabled the identification of genes and cis-regulatory regions
involved in normal and pathological hematopoiesis. Cis-regulatory
elements represent in some cases potential therapeutic targets.
The recent advent of genome editing technologies offers great
promise for the development of targeted therapeutic approaches.
Future studies will address the efficiency, efficacy, and safety of
novel therapeutic strategies aimed at modulating gene expression
by targeting cis-regulatory regions.
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